NGL Fine Chem Q4 FY26: Capex ₹210 Cr
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹149Cr
- +56.8% YoY
- +16.4% QoQ
- Net profit
- ₹13Cr
- +1200% YoY
- −18.7% QoQ
- Margin
- 14%
- +7 pp YoY
- −4 pp QoQ
Guidance rank: #35 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
2 of 4 strong
The short version
Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.
From NGL Fine Chem's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies.
- Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates.
- New plant expansions are expected to add up to Rs. 350 crores in turnover over the next 3-4 years.
- Regulated market sales (Europe starting FY27, US from FY28) will contribute meaningfully from FY28 onwards, though peak contributions are still to be crystallized.
- The company aims to stabilize at a quarterly run rate of approx. Rs. 150 crore, with potential to exceed it over time.
- Continued addition of 9-10 new products annually supports diversified growth.
2 more points from NGL Fine Chem's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
- Phase II Greenfield expansion at Tarapur faced delays due to gas and labor shortages; commissioning rescheduled from Q1 FY27 to early Q2 FY27.
- Commercial production for Phase II is expected to start from H2 FY27, as previously guided.
- Post project completion, annual CAPEX is expected to be around ₹15-20 crores.
- No additional large-scale CAPEX currently planned beyond this expansion.
- Management is financing the cost increase internally, without additional borrowing.
2 more points from NGL Fine Chem's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from NGL Fine Chem's call on order book
Create a free account to keep reading this call
NGL Fine Chem — Quarterly revenue & net profit
NGL Fine Chem Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 149 | 95 | +56.8% | 128 | +16.4% |
| Operating profit (EBITDA) | 21 | 6 | +250% | 22 | -4.5% |
| Operating margin | 14% | 7% | +7 pp | 18% | -4 pp |
| Profit before tax | 18 | 1 | +1700% | 21 | -14.3% |
| Net profit (PAT) | 13 | 1 | +1200% | 16 | -18.7% |
| EPS (₹) | 21.84 | 0.87 | +2410.3% | 25.40 | -14% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Q4 FY26 results?
Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.
What is NGL Fine Chem share price analysis?
NGL Fine Chem currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem planning capital expenditure?
Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
